KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Net Margin (2016 - 2025)

Historic Net Margin for Travere Therapeutics (TVTX) over the last 12 years, with Q4 2024 value amounting to 0.01%.

  • Travere Therapeutics' Net Margin rose 35100.0% to 0.01% in Q4 2024 from the same period last year, while for Sep 2025 it was 0.0%, marking a year-over-year increase of 12500.0%. This contributed to the annual value of 0.39% for FY2024, which is 1828100.0% down from last year.
  • According to the latest figures from Q4 2024, Travere Therapeutics' Net Margin is 0.01%, which was up 35100.0% from 0.16% recorded in Q3 2024.
  • Over the past 5 years, Travere Therapeutics' Net Margin peaked at 646.92% during Q3 2023, and registered a low of 238.55% during Q4 2020.
  • For the 5-year period, Travere Therapeutics' Net Margin averaged around 19.29%, with its median value being 0.08% (2024).
  • In the last 5 years, Travere Therapeutics' Net Margin surged by 5956100bps in 2023 and then crashed by -6470800bps in 2024.
  • Over the past 5 years, Travere Therapeutics' Net Margin (Quarter) stood at 238.55% in 2020, then surged by 124bps to 56.1% in 2021, then increased by 20bps to 67.53% in 2022, then tumbled by -105bps to 3.5% in 2023, then surged by 100bps to 0.01% in 2024.
  • Its Net Margin was 0.01% in Q4 2024, compared to 0.16% in Q3 2024 and 1.4% in Q2 2024.